Among them, the overexpression of human epidermal growth factor receptor 2 (HER2, also called ErbB2) occurs in roughly 15-20% of breast cancers and is associated with aggressive proliferation and poor prognosis [2]. This evidence concerns the gene ERBB2 and breast cancer.